Δημοσίευση

Effects of rich-in-fat diets and highly selective COX-2 inhibitors on 7,12-dimethylbenz-(A)-anthracene-induced tumor growth.

ΤίτλοςEffects of rich-in-fat diets and highly selective COX-2 inhibitors on 7,12-dimethylbenz-(A)-anthracene-induced tumor growth.
Publication TypeJournal Article
Year of Publication2009
AuthorsMiliaras, S., Anogeianaki A., Meditskou S., Kefala V., Koutsonikolas D., Liangouris J., Anogianakis G., & Miliaras D.
JournalInt J Immunopathol Pharmacol
Volume22
Issue2
Pagination323-32
Date Published2009 Apr-Jun
ISSN0394-6320
Λέξεις κλειδιά9,10-Dimethyl-1,2-benzanthracene, Adenocarcinoma, Animals, Anticarcinogenic Agents, Caloric Restriction, Cell Transformation, Neoplastic, Cyclooxygenase 2, Cyclooxygenase 2 Inhibitors, Dietary Fats, Female, Mammary Neoplasms, Animal, Neoplasms, Pyrazoles, Rats, Rats, Sprague-Dawley, Sarcoma, Sulfonamides, Time Factors
Abstract

The effects of diet, of non-steroidal anti-inflammatory drugs, or of their combination on carcinogenesis continue to be a case for controversy. Diets that are high in fat have been linked to increased risk of various tumors. At the same time there is substantial, but not conclusive, evidence that the risk of breast and colon cancer correlates with total fat intake rather than a specific type of fat. On the other hand, non-steroidal anti-inflammatory drugs (NSAIDs) have been studied extensively because they appear to delay or inhibit the development of malignant and pre-malignant lesions. 7,12-Dimethylbenz-(a)-anthracene (DMBA) has been used for a long time to induce carcinogenesis in a number of rat animal models. The present study attempts to identify the effects on DMBA-induced tumor growth (a) of diets rich in fat and (b) of the highly selective COX-2 inhibitor Celecoxib, which has been claimed to offer substantial protection against carcinogenesis.

Alternate JournalInt J Immunopathol Pharmacol
PubMed ID19505386

Επικοινωνία

Γραμματεία Τμήματος Ιατρικής T.K. 54124 Θεσσαλονίκη
 

Συνδεθείτε

Το τμήμα Ιατρικής στα social networks.
Ακολουθήστε μας ή συνδεθείτε μαζί μας.